Tema Etfs LLC Takes Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Tema Etfs LLC bought a new stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 11,352 shares of the biopharmaceutical company's stock, valued at approximately $237,000.

A number of other large investors also recently added to or reduced their stakes in the business. Summit Investment Advisors Inc. lifted its position in Catalyst Pharmaceuticals by 5.2% during the 4th quarter. Summit Investment Advisors Inc. now owns 11,696 shares of the biopharmaceutical company's stock valued at $244,000 after purchasing an additional 580 shares during the period. Bank of Montreal Can raised its position in shares of Catalyst Pharmaceuticals by 6.2% in the 4th quarter. Bank of Montreal Can now owns 14,879 shares of the biopharmaceutical company's stock valued at $311,000 after acquiring an additional 875 shares during the period. Rhumbline Advisers raised its position in shares of Catalyst Pharmaceuticals by 0.3% in the 4th quarter. Rhumbline Advisers now owns 312,320 shares of the biopharmaceutical company's stock valued at $6,518,000 after acquiring an additional 952 shares during the period. Handelsbanken Fonder AB raised its position in shares of Catalyst Pharmaceuticals by 2.9% in the 4th quarter. Handelsbanken Fonder AB now owns 35,477 shares of the biopharmaceutical company's stock valued at $740,000 after acquiring an additional 1,000 shares during the period. Finally, PDT Partners LLC raised its position in shares of Catalyst Pharmaceuticals by 5.2% in the 4th quarter. PDT Partners LLC now owns 20,664 shares of the biopharmaceutical company's stock valued at $431,000 after acquiring an additional 1,030 shares during the period. 79.22% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. Baird R W upgraded shares of Catalyst Pharmaceuticals to a "strong-buy" rating in a research report on Monday, February 3rd. Stephens reiterated an "overweight" rating and issued a $33.00 price target on shares of Catalyst Pharmaceuticals in a research report on Thursday, February 27th. Wall Street Zen upgraded shares of Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Friday, February 28th. Robert W. Baird increased their price target on shares of Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the company an "outperform" rating in a research report on Monday, March 3rd. Finally, HC Wainwright reiterated a "buy" rating and issued a $35.00 price target on shares of Catalyst Pharmaceuticals in a research report on Friday, February 28th. Seven investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, Catalyst Pharmaceuticals currently has an average rating of "Buy" and an average target price of $32.29.

Insider Transactions at Catalyst Pharmaceuticals

In other news, insider Gary Ingenito sold 44,000 shares of the firm's stock in a transaction that occurred on Wednesday, May 14th. The shares were sold at an average price of $23.63, for a total transaction of $1,039,720.00. Following the completion of the transaction, the insider now directly owns 68,873 shares of the company's stock, valued at $1,627,468.99. This trade represents a 38.98% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Brian Elsbernd sold 62,975 shares of the firm's stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $22.98, for a total transaction of $1,447,165.50. Following the transaction, the insider now directly owns 188,564 shares of the company's stock, valued at $4,333,200.72. This represents a 25.04% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 351,879 shares of company stock valued at $8,214,815 in the last ninety days. 10.40% of the stock is currently owned by corporate insiders.

Catalyst Pharmaceuticals Stock Performance

NASDAQ CPRX traded up $0.38 during trading hours on Friday, reaching $24.49. 772,723 shares of the company's stock were exchanged, compared to its average volume of 1,106,163. The company's 50-day moving average is $23.53 and its two-hundred day moving average is $22.56. Catalyst Pharmaceuticals, Inc. has a one year low of $14.75 and a one year high of $26.16. The company has a market capitalization of $2.99 billion, a price-to-earnings ratio of 20.75, a price-to-earnings-growth ratio of 3.31 and a beta of 0.70.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.